Wattenburg v. United Medical Laboratories, Inc.

525 P.2d 113, 269 Or. 377, 1974 Ore. LEXIS 395
CourtOregon Supreme Court
DecidedAugust 8, 1974
StatusPublished
Cited by36 cases

This text of 525 P.2d 113 (Wattenburg v. United Medical Laboratories, Inc.) is published on Counsel Stack Legal Research, covering Oregon Supreme Court primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Wattenburg v. United Medical Laboratories, Inc., 525 P.2d 113, 269 Or. 377, 1974 Ore. LEXIS 395 (Or. 1974).

Opinion

DENECKE, J.

The jury returned a verdict for the defendants in this slander case. The trial court, however, granted the plaintiff’s motion for a new trial upon the ground that one of the defendants’ attorneys made an improper closing argument. The defendants appeal.

The defendants contend that the trial court erred in denying their motion for a directed verdict. If the defendants are correct, whether the trial court erred in ordering a new trial becomes immaterial.

The defendants admit the utterance of the defamatory statements. The issues on the motion for a directed verdict are whether the utterance was conditionally privileged and, if so, whether there was evidence that the defendants made the statement with malice, thus destroying the protection of the privilege.

A defamatory statement is privileged if it is uttered under such circumstances that the law grants immunity to the speaker. The privilege is conditional rather than absolute because the privilege is lost if the statement is made maliciously.

If the occasion was one for privileged speech, there was evidence of malice. For this reason the trial court was correct in denying the motion for a directed verdict.

Whether the statement was made maliciously depends at least in part on whether the statement was *380 made for the purpose for which the privilege was created. For this reason it is necessary to state the basis on which defendants contend the statement was privileged.

A statement is conditionally privileged if: (1) it was made to protect the interests of defendants; (2) it was made to protect the interests of plaintiff’s employer; or (3) it was on a subject of mutual concern to defendants and the persons to whom the statement was made. 3 Restatement 242, Torts §§ 594-596. Defendants contend the statement in this case was privileged for all of these reasons.

The malice required is something more than “implied” or “legal” malice. The plaintiff must offer evidence of some kind of improper motive on defendant’s part.

The defendant United Medical Laboratories (UML) is a Portland based clinical testing laboratory to which physicians send blood, urine, etc., for testing. The defendant Michel is the president, founder and chief officer of UML. The plaintiff and a colleague founded Berkeley Scientific Laboratories (BSL) which designs computer systems for medical testing facilities. In 1968 BSL was sold to Tracor and plaintiff remained with BSL under an employment contract.

BSL did special engineering work for UML and sold it several systems. Plaintiff represented BSL in at least some of these transactions. In the latter part of 1969 BSL contracted with UML to furnish a hematology data analysis system and a programming system for a total price of $179,000. Plaintiff represented BSL in the sale.

BSL and plaintiff learned that defendants con *381 sidered this contract for purchase to he revocable. Plaintiff came to Portland to dissuade defendants from canceling their contract. On January 26, 1970, defendants executed a letter agreement in which defendants promised not to cancel the order but to change the system to be purchased to a Clindata system. In June 1970, however, defendants canceled the January order. Subsequently, the parties negotiated in an attempt to resolve the controversy over the cancellation of this order.

Dr. Larsen is an executive of UML. He had some role in the decision to purchase the Clindata system from BSL. Mr. Dexter was a vice president for laboratory operations for UML.

Dr. Larsen was in Sweden in 1969. He met a Swedish girl who was trying to find a position in the United States. When Dr. Larsen returned to the United States and was at BSL he told plaintiff about the girl and her desire for a job. Plaintiff had the personnel department investigate and as a result the girl came to the United States and was hired by BSL.

Dr. Larsen testified that in August or September 1970 he received a telephone call from plaintiff. He testified plaintiff told him he wanted his help in persuading UML to accept the system they had ordered because if UML did not plaintiff would be in trouble with the concern that purchased BSL, that is Tracor. Dr. Larsen also testified that plaintiff told him plaintiff knew Dr. Larsen had a problem with this Swedish girl because Larsen had made a trip to Norway with her; that if this got back to the defendant Michel, Larsen would get fired. Larsen replied that he had nothing to hide in his relationship with the Swedish girl.

*382 Mr. Dexter testified that in September 1970 he received a telephone call from plaintiff. Dexter testified plaintiff said there was a problem with Dr. Larsen and a Swedish girl “and it could get very-sticky, and the way to solve the whole situation was to take the system [Clindata] and he would do his best to keep the situation quiet at B.S.L. and U.M.L.”

There was evidence that Dexter told Michel of the threats and that Larsen told Michel either that plaintiff had threatened him or that Dexter had told Larsen that plaintiff had told Dexter plaintiff might expose Larsen.

On October 13, 1970, plaintiff wrote UML that an agreement had to be reached in their controversy about the Clindata system by October 20th. On October 19th the president of Tracor sent two Tracor executives, Messrs. Hubbard and Schutt, to Portland to meet with UML and discuss the controversy. In the course of the ensuing discussions, Michel and Dexter testified that the Tracor executive asked “why do you want to get out of this business relationship,” or words to that effect. Michel replied that plaintiff was attempting blackmail or exerting unethical pressure against Dr. Larsen in an attempt to get UML to accept the Clindata system. Later, in the same meeting, Michel repeated the accusation.

That same day Mr. Hubbard, the Tracor executive who was conferring with Michel, called plaintiff and relieved him of his duties as chief executive of BSL.

There was evidence that in the fall of 1970 UML restricted its purchases for financial reasons. There was also evidence that by 1970 UML was developing *383 the capabilities of producing an analysis system similar to the kind sold by BSL.

Plaintiff contends that there was evidence from which the jury could find the defendant Michel did not believe that the plaintiff had tried to blackmail Dr. Larsen. All agree, except in circumstances not here relevant, that if the one who publishes does not believe the statement uttered, the publisher has acted maliciously.

Section 600, 3 Restatement 264, Torts, states:

“Except as stated in § 602, one who upon a conditionally privileged occasion publishes false and defamatory matter of another abuses the occasion if he does not believe in the truth of the defamatory matter.”

Prosser states the principle: “Finally, since there is no social advantage in the publication of a deliberate lie, the privilege is lost if the defendant does not believe what he savs.” Prosser, Law of Torts (4th ed) 795, § 115.

The plaintiff has the burden of proving malice.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Madsen v. Versus, Inc.
Court of Appeals of Oregon, 2026
Wahab v. Wahab
D. Oregon, 2024
Mannex Corp. v. Bruns
279 P.3d 278 (Court of Appeals of Oregon, 2012)
Kofoed v. Shiprack
200 F. App'x 646 (Ninth Circuit, 2006)
Morlan v. Qwest Dex, Inc.
156 F. App'x 949 (Ninth Circuit, 2005)
I.C. Marketing, Inc. v. Amos Press, Inc.
147 F. App'x 671 (Ninth Circuit, 2005)
Morlan v. Qwest Dex, Inc.
332 F. Supp. 2d 1356 (D. Oregon, 2004)
Lansford v. Georgetown Manor, Inc.
84 P.3d 1105 (Court of Appeals of Oregon, 2004)
Affolter v. Baugh Construction Oregon, Inc.
51 P.3d 642 (Court of Appeals of Oregon, 2002)
DeLong v. Yu Enterprises, Inc.
47 P.3d 8 (Oregon Supreme Court, 2002)
Hulse v. Ocwen Federal Bank, FSB
195 F. Supp. 2d 1188 (D. Oregon, 2002)
Kofoed v. Rosendin Electric, Inc.
157 F. Supp. 2d 1152 (D. Oregon, 2001)
Palchikovskiy v. Oregon Health Sciences University
14 F. App'x 898 (Ninth Circuit, 2001)
Ishikawa v. Delta Air Lines, Inc.
149 F. Supp. 2d 1246 (D. Oregon, 2001)
Araujo v. General Electric Information Services
82 F. Supp. 2d 1161 (D. Oregon, 2000)
Bendl v. Parks
994 P.2d 802 (Court of Appeals of Oregon, 2000)
Kraemer v. Harding
976 P.2d 1160 (Court of Appeals of Oregon, 1999)
Vanderselt v. Pope
963 P.2d 130 (Court of Appeals of Oregon, 1998)
Muresan v. Philadelphia Romanian Pentecostal Church
962 P.2d 711 (Court of Appeals of Oregon, 1998)
Hayhurst v. Kruzel
111 F.3d 138 (Ninth Circuit, 1997)

Cite This Page — Counsel Stack

Bluebook (online)
525 P.2d 113, 269 Or. 377, 1974 Ore. LEXIS 395, Counsel Stack Legal Research, https://law.counselstack.com/opinion/wattenburg-v-united-medical-laboratories-inc-or-1974.